Daniel A Norris

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Venues

Nature medicine

CPT: pharmacometrics & systems pharmacology

Bioanalysis

This page only lists publications with an associated author ORCID identifier.

Publications

Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O Rinne, Albert C Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A Norris, Rebecca Crean, Danielle L Graham, Ellen Huang, Elena Ratti, C Frank Bennett, Candice Junge, Roger M Lane
Author Correction: Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature medicine (2023)
Yumi Yamamoto, Patricia Sanwald Ducray, Marcus Björnsson, Kevin Smart, Paul Grimsey, Suresh Vatakuti, Agnes Portron, Benoit Massonnet, Daniel A Norris, Hanna E Silber Baumann
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma. CPT: pharmacometrics & systems pharmacology (2023)
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O Rinne, Albert C Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A Norris, Rebecca Crean, Danielle L Graham, Ellen Huang, Elena Ratti, C Frank Bennett, Candice Junge, Roger M Lane
Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature medicine (2023)
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O Rinne, Albert C Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A Norris, Rebecca Crean, Danielle L Graham, Ellen Huang, Elena Ratti, C Frank Bennett, Candice Junge, Roger M Lane
Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature medicine (2023)
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O Rinne, Albert C Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A Norris, Rebecca Crean, Danielle L Graham, Ellen Huang, Elena Ratti, C Frank Bennett, Candice Junge, Roger M Lane
Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature medicine (2023)
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O Rinne, Albert C Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A Norris, Rebecca Crean, Danielle L Graham, Ellen Huang, Elena Ratti, C Frank Bennett, Candice Junge, Roger M Lane
Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature medicine (2023)
Daniel A Norris, Noah Post, Rosie Z Yu, Sarah Greenlee, Yanfeng Wang
Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics. Bioanalysis 11 (21) (2019)

Daniel A Norris.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel A Norris